Extrawell Pharmaceutical Holdings Limited (0858.HK)
HKD 0.05
(2.04%)
HKD 0.05
(2.04%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 117.12 Million HKD | -80.83% |
| 2022 | 610.97 Million HKD | 2.61% |
| 2021 | 595.43 Million HKD | 2.25% |
| 2020 | 582.33 Million HKD | 1.93% |
| 2019 | 571.3 Million HKD | 1051.02% |
| 2018 | 49.63 Million HKD | 18.71% |
| 2017 | 41.81 Million HKD | 18.71% |
| 2016 | 35.22 Million HKD | 18.71% |
| 2015 | 29.67 Million HKD | 18.77% |
| 2014 | 24.98 Million HKD | -80.57% |
| 2013 | 128.59 Million HKD | 442.63% |
| 2012 | 23.69 Million HKD | 393.01% |
| 2011 | 4.8 Million HKD | 0.0% |
| 2010 | - HKD | 0.0% |
| 2009 | - HKD | 0.0% |
| 2008 | - HKD | 0.0% |
| 2007 | - HKD | 0.0% |
| 2006 | - HKD | 0.0% |
| 2005 | - HKD | 0.0% |
| 2004 | - HKD | 0.0% |
| 2003 | - HKD | 0.0% |
| 2002 | - HKD | 0.0% |
| 2001 | - HKD | 0.0% |
| 2000 | - HKD | 0.0% |
| 1999 | - HKD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 FY | 117.12 Million HKD | -80.83% |
| 2023 Q2 | 619.83 Million HKD | 0.0% |
| 2023 Q4 | 117.12 Million HKD | 0.0% |
| 2022 Q2 | 602.89 Million HKD | 0.0% |
| 2022 FY | 610.97 Million HKD | 2.61% |
| 2022 Q4 | 610.97 Million HKD | 0.0% |
| 2021 Q2 | 588.62 Million HKD | 0.0% |
| 2021 Q4 | 595.43 Million HKD | 0.0% |
| 2021 FY | 595.43 Million HKD | 2.25% |
| 2020 Q4 | 582.33 Million HKD | 0.0% |
| 2020 FY | 582.33 Million HKD | 1.93% |
| 2020 Q2 | 576.6 Million HKD | 0.0% |
| 2019 FY | 571.3 Million HKD | 1051.02% |
| 2019 Q2 | 566.45 Million HKD | 0.0% |
| 2019 Q4 | 571.3 Million HKD | 0.0% |
| 2018 Q2 | 45.56 Million HKD | 0.0% |
| 2018 Q4 | 49.63 Million HKD | 0.0% |
| 2018 FY | 49.63 Million HKD | 18.71% |
| 2017 FY | 41.81 Million HKD | 18.71% |
| 2017 Q4 | 41.81 Million HKD | 0.0% |
| 2017 Q2 | 38.38 Million HKD | 0.0% |
| 2016 Q2 | 32.33 Million HKD | 0.0% |
| 2016 FY | 35.22 Million HKD | 18.71% |
| 2016 Q4 | 35.22 Million HKD | 0.0% |
| 2015 Q1 | 27.22 Million HKD | 8.98% |
| 2015 Q4 | 29.67 Million HKD | 0.0% |
| 2015 FY | 29.67 Million HKD | 18.77% |
| 2015 Q2 | 27.22 Million HKD | 0.0% |
| 2014 Q1 | 125.9 Million HKD | -2.09% |
| 2014 FY | 24.98 Million HKD | -80.57% |
| 2014 Q4 | 24.98 Million HKD | 0.0% |
| 2014 Q3 | 24.98 Million HKD | -80.16% |
| 2014 Q2 | 125.9 Million HKD | 0.0% |
| 2013 Q2 | 116.27 Million HKD | -12.01% |
| 2013 Q4 | 128.59 Million HKD | 231.32% |
| 2013 Q3 | 38.81 Million HKD | -66.62% |
| 2013 Q1 | 132.14 Million HKD | 2103.54% |
| 2013 FY | 128.59 Million HKD | 442.63% |
| 2012 Q2 | 5.99 Million HKD | -73.73% |
| 2012 Q1 | 22.83 Million HKD | 375.02% |
| 2012 FY | 23.69 Million HKD | 393.01% |
| 2012 Q4 | 5.99 Million HKD | -74.7% |
| 2012 Q3 | 23.69 Million HKD | 295.12% |
| 2011 Q4 | 4.8 Million HKD | 0.0% |
| 2011 FY | 4.8 Million HKD | 0.0% |
| 2011 Q2 | 4.8 Million HKD | 0.0% |
| 2010 FY | - HKD | 0.0% |
| 2010 Q4 | - HKD | 0.0% |
| 2010 Q2 | - HKD | 0.0% |
| 2009 Q4 | - HKD | 0.0% |
| 2009 FY | - HKD | 0.0% |
| 2008 FY | - HKD | 0.0% |
| 2007 FY | - HKD | 0.0% |
| 2006 FY | - HKD | 0.0% |
| 2005 FY | - HKD | 0.0% |
| 2004 FY | - HKD | 0.0% |
| 2003 FY | - HKD | 0.0% |
| 2002 FY | - HKD | 0.0% |
| 2001 FY | - HKD | 0.0% |
| 2000 FY | - HKD | 0.0% |
| 1999 FY | - HKD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -5549.979% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 88.17% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 57.594% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | -65.813% |
| Essex Bio-Technology Limited | 36.05 Million HKD | -224.833% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -814.96% |
| PuraPharm Corporation Limited | 81.09 Million HKD | -44.432% |
| SSY Group Limited | 1.94 Billion HKD | 93.986% |
| JBM (Healthcare) Limited | 43.8 Million HKD | -167.406% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 80.222% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.295% |